Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China · Delayed Price · Currency is CNY 64.39
-2.12 (-3.19%)
Feb 13, 2026, 3:00 PM CST
SHA:688513 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 241.37 | 238.23 | 226.57 | 246.52 | 232.43 | 178.16 |
Depreciation & Amortization | 81.37 | 81.37 | 73.23 | 58.35 | 32.6 | 32.98 |
Other Amortization | 3.14 | 3.14 | 1.49 | 1.34 | 1.19 | 0.96 |
Loss (Gain) From Sale of Assets | 0 | 0 | -0.13 | -0.26 | - | 0.01 |
Asset Writedown & Restructuring Costs | 0.11 | 0.11 | 0.11 | 0.07 | 0.1 | - |
Loss (Gain) From Sale of Investments | -24.76 | -24.76 | -25.48 | -27.84 | -42.04 | -9.53 |
Provision & Write-off of Bad Debts | 3.03 | 3.03 | -0.36 | 1.42 | -2.25 | 2.11 |
Other Operating Activities | 78.37 | 9.34 | 6.12 | 4.81 | 2.24 | 2.74 |
Change in Accounts Receivable | -112.44 | -112.44 | -75.72 | -51.53 | -181.32 | -121.69 |
Change in Inventory | -34.8 | -34.8 | -22.74 | -39.5 | -21.55 | -25.58 |
Change in Accounts Payable | 82.73 | 82.73 | 90.2 | -45.57 | 129.14 | 104.75 |
Change in Other Net Operating Assets | 19.98 | 19.98 | 1.23 | -0.06 | 0.39 | -3.07 |
Operating Cash Flow | 335.41 | 263.24 | 275.25 | 151.94 | 147.6 | 156.52 |
Operating Cash Flow Growth | 49.64% | -4.36% | 81.15% | 2.95% | -5.70% | 10.36% |
Capital Expenditures | -83.14 | -117.42 | -175.26 | -339.33 | -270.19 | -198.81 |
Sale of Property, Plant & Equipment | 1.83 | 0.49 | 0.26 | 0.33 | - | 0.1 |
Investment in Securities | 295.38 | 313.56 | -234.53 | -81.41 | 160.61 | -559.74 |
Other Investing Activities | -447.39 | - | -0.65 | 14.71 | -1.01 | 1.82 |
Investing Cash Flow | -233.33 | 196.63 | -410.17 | -405.7 | -110.59 | -756.63 |
Short-Term Debt Issued | - | - | - | - | 30 | 40 |
Long-Term Debt Issued | - | 150 | 235 | 100 | - | - |
Total Debt Issued | 85 | 150 | 235 | 100 | 30 | 40 |
Short-Term Debt Repaid | - | - | - | - | -50 | - |
Long-Term Debt Repaid | - | -253.92 | -91.48 | -50 | - | - |
Total Debt Repaid | -152.93 | -253.92 | -91.48 | -50 | -50 | - |
Net Debt Issued (Repaid) | -67.93 | -103.92 | 143.52 | 50 | -20 | 40 |
Issuance of Common Stock | 9.6 | 34.76 | - | - | - | 1,244 |
Common Dividends Paid | -77.53 | -74.11 | -71.08 | -96.05 | -36.4 | -0.7 |
Other Financing Activities | 11.47 | -118.99 | 8.22 | 85.74 | - | -31.83 |
Financing Cash Flow | -124.4 | -262.27 | 80.67 | 39.7 | -56.4 | 1,251 |
Foreign Exchange Rate Adjustments | 0.07 | 0.03 | -0.07 | 0.02 | -0.01 | -0.02 |
Net Cash Flow | -22.24 | 197.64 | -54.32 | -214.04 | -19.39 | 651.23 |
Free Cash Flow | 252.27 | 145.82 | 99.99 | -187.38 | -122.59 | -42.28 |
Free Cash Flow Growth | 129.42% | 45.83% | - | - | - | - |
Free Cash Flow Margin | 18.98% | 10.80% | 8.95% | -16.01% | -11.98% | -4.59% |
Free Cash Flow Per Share | 1.43 | 0.83 | 0.56 | -1.06 | -0.70 | -0.29 |
Cash Income Tax Paid | 151.11 | 147.05 | 91.73 | 108.05 | 118.32 | 118.2 |
Levered Free Cash Flow | 94.6 | -13.92 | 47.75 | -258.5 | -90.64 | -59.72 |
Unlevered Free Cash Flow | 96.23 | -11.62 | 49.89 | -256.87 | -90.41 | -59.27 |
Change in Working Capital | -47.22 | -47.22 | -6.3 | -132.46 | -76.67 | -50.9 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.